ADSVF ( DrugBank: - )
2 diseases
ID | Disease name (Link within this page) | Number of trials |
---|---|---|
15 | Inclusion body myositis | 1 |
96 | Crohn disease | 1 |
15. Inclusion body myositis
Clinical trials : 42 / Drugs : 33 - (DrugBank : 11) / Drug target genes : 12 - Drug target pathways : 123
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT05032131 (ClinicalTrials.gov) | September 2021 | 27/8/2021 | Cell Therapy for IBM by Muscle Injection of ADSVF: a Phase I Trial | Cell Therapy for Inclusion Body Myositis (IBM) by Muscle Injection of Autologous Uncultured Adipose-Derived Stromal Vascular Fraction (ADSVF): a Phase I Trial | Inclusion Body Myositis | Biological: ADSVF | Assistance Publique - Hôpitaux de Paris | NULL | Not yet recruiting | 45 Years | 80 Years | All | 32 | Phase 1 | NULL |
96. Crohn disease
Clinical trials : 2,442 / Drugs : 1,278 - (DrugBank : 248) / Drug target genes : 142 - Drug target pathways : 209
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | EUCTR2019-001948-21-FR (EUCTR) | 03/09/2019 | 15/05/2019 | Double-blind randomised placebo controlled study evaluating local co-administration of autologous ADIpose derived stromal vascular fraction with microfat for refractory perianal CROHN’s fistulas. | Double-blind randomised placebo controlled study evaluating local co-administration of autologous ADIpose derived stromal vascular fraction with microfat for refractory perianal CROHN’s fistulas. - ADICROHN-II | Crohn’s disease;Therapeutic area: Diseases [C] - Immune System Diseases [C20] | Product Name: autologous ADIpose derived stromal vascular fraction Product Code: ADSVF Trade Name: vialebex 200mg Product Name: VIALEBEX Product Code: SERUM ALBUMINE 5% INN or Proposed INN: ALBUMINE HUMAINE Other descriptive name: HUMAN ALBUMIN AS MACROAGGREGATES Trade Name: serum physiologique 0.9 % Product Name: chlorure de sodium INN or Proposed INN: CHLORURE DE SODIUM Other descriptive name: SODIUM CHLORIDE | ASSISTANCE PUBLIQUE HOPITAUX DE MARSEILLE | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 84 | Phase 2 | France |